Is CGC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Core cannabis business back to growth, with revenue (ttm) at ~$294 million (reported in Canadian dollars), with the June 2026 quarter up ~12.5% year over year. The bear case rests on the central risk is that Canopy is still unprofitable in a brutally competitive industry. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The central risk is that Canopy is still unprofitable in a brutally competitive industry. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Core cannabis business back to growth. After years of shrinking revenue, Canopy reported that fiscal 2026 brought its cannabis business back to top-line growth, with double-digit gains in Canadian adult-use, Canadian medical, and international cannabis.

The central risk is that Canopy is still unprofitable in a brutally competitive industry. Canadian adult-use cannabis suffers from oversupply and price compression, which squeezes margins even as volumes grow. The company has a long history of large writedowns (BioSteel, Wana, and others) and heavy share dilution, so existing shareholders have repeatedly been diluted to fund losses. Its US upside through Canopy USA depends on federal reform that has been promised for years without arriving, and remains outside the company's control. Canopy also restated prior-period financials for non-cash technical errors tied to certain US-dollar share-settled warrants. As a small-cap cannabis stock, CGC is highly volatile and sensitive to sentiment, financing conditions, and regulatory headlines, with no guarantee the turnaround reaches sustained profitability. A newer risk is the share price itself: CGC closed at $0.74 on October 16, 2026, and Nasdaq rules require a minimum $1 bid price, so a prolonged stretch below $1 could bring a deficiency notice and another reverse split, as the company has done before.

Canopy Growth Corporation is one of Canada's largest cannabis companies, based in Smiths Falls, Ontario.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Core cannabis business back to growth) stalling in the reported numbers rather than in the narrative, the risk above (the central risk is that Canopy is still unprofitable in a brutally competitive industry) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a genuine turnaround: core cannabis revenue back to growth, losses roughly halved, a net-cash balance sheet, and US optionality through Canopy USA. The bear case is that Canopy is still unprofitable, has diluted shareholders heavily, competes in an oversupplied market, and depends on US reform that keeps being delayed. The shares are down about 38% in 2026 and trade below $1. It is a speculative, high-volatility holding.

Canopy is a Canadian cannabis company. It grows and sells adult-use and medical cannabis in Canada under brands like Tweed and Doja, exports medical cannabis to international markets such as Europe and Australia, and owns Storz & Bickel, a maker of premium vaporizer devices. It also holds US cannabis assets through a separate structure called Canopy USA, meant to activate when federal law allows.

No, not yet. Canopy remains net-loss-making, though in fiscal 2026 it narrowed its net loss from continuing operations to roughly half the prior year's level and returned its core cannabis business to revenue growth. A January 2026 recapitalization also left it with a net-cash position. Reaching sustained profitability is the central open question for the stock, and there is no guarantee it gets there.